Global containment of COVID-19 still requires accessible and affordable vaccines for low-
and middle-income countries (LMICs). 1 Recently approved vaccines provide needed …

Background Mucosal antibodies can prevent virus entry and replication in mucosal epithelial
cells and hence virus shedding. Parenteral booster injection of a vaccine against a mucosal …

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to
emerge and spread around the world, antibodies and vaccines to confer broad and potent …

To address the COVID-19 pandemic, there has been an unprecedented global effort to
advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical …

SARS-CoV-2 variants that attenuate antibody neutralization could jeopardize vaccine
efficacy. We recently reported the protective activity of an intranasally administered spike …

Antibody therapeutics for the treatment of COVID-19 have been highly successful. However,
the recent emergence of the Omicron variant has posed a challenge, as it evades detection …

The current SARS-CoV-2 variants strikingly evade all authorized monoclonal antibodies and
threaten the efficacy of serum-neutralizing activity elicited by vaccination or prior infection …

The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in
the face of the global COVID-19 pandemic, as such reagents can have important diagnostic …

Detection of secretory antibodies in the airway is highly desirable when evaluating mucosal
protection by vaccines against a respiratory virus, such as the severe acute respiratory …

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has resulted in over 100 million infections and millions of deaths. Effective vaccines remain …